Mga Batayang Estadistika
| LEI | 549300KPNOKI02O2ZP21 |
| CIK | 1289340 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Stereotaxis, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 29, 2025 STEREOTAXIS, INC. |
|
| August 29, 2025 |
STEREOTAXIS, INC. Common Stock ($0.001 par value per share) Sales Agreement Exhibit 1.1 STEREOTAXIS, INC. $50,000,000 Common Stock ($0.001 par value per share) Sales Agreement August 29, 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Stereotaxis, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Roth Capital Partners, LLC (the “Agent”), as follows: 1. Issuance and S |
|
| August 29, 2025 |
Up to $50,000,000 Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-272102 PROSPECTUS SUPPLEMENT (To the prospectus dated June 6, 2023) Up to $50,000,000 Common Stock On August 29, 2025, we entered into a Sales Agreement (“Sales Agreement”) with Roth Capital Partners, LLC as sales agent (“Roth”) relating to the sale of shares of our common stock, par value $0.001 per share, offered by this prospectus supplement |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): August 7, 2025 STEREOTAXIS, INC. |
|
| August 7, 2025 |
Stereotaxis Reports 2025 Second Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2025 Second Quarter Financial Results St. Louis, MO, August 7, 2025 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2025. “We are pleased with our commercial results in the quarter. Sequential and yea |
|
| July 18, 2025 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-272102 PROSPECTUS SUPPLEMENT (To the prospectus dated May 19, 2023) 6,250,000 Shares COMMON STOCK We are selling 6,250,000 shares of our common stock under this prospectus supplement and the accompanying prospectus directly to certain investors (the “Investors”) at a price of $2.00 per share pursuant to a securities purchase agreement (the “Pur |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 17, 2025 STEREOTAXIS, INC. |
|
| July 17, 2025 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT July 17, 2025 David L. Fischel Chief Executive Officer Stereotaxis, Inc. 710 North Tucker Boulevard Suite 110 St. Louis, Missouri 63101 Dear Mr. Fischel: This letter agreement (the “Agreement”) constitutes the agreement between Lake Street Capital Markets, LLC (“Lake Street”), as placement agent (the “Placement Agent”) and Stereotaxis, Inc., a company incorp |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 17, 2025 STEREOTAXIS, INC. |
|
| July 17, 2025 |
Exhibit 10.2 FORM OF SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of July 17, 2025, by and between Stereotaxis, Inc., a Delaware corporation (the “Company”), and each of the investors executing the signature pages attached hereto (each, an “Investor” and collectively, the “Investors”). WHEREAS, the Company has filed with the U.S. Securities and Exchange |
|
| July 17, 2025 |
Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock Exhibit 99.1 Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock ● Led by Strategic Industry Partner and Select Institutional Investors ● Proceeds Strengthen Balance Sheet and Support Commercialization of Innovation Strategy St. Louis, July 17, 2025 (Globe Newswire) – Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Stereotaxis, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36159 94-3120386 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification No.) 710 N. Tucker Blvd, Suite 110; St. Louis, MO 63101 (Address of pr |
|
| June 2, 2025 |
Stereotaxis, Inc. Conflict Minerals Report for the reporting period January 1 to December 31, 2024 Exhibit 1.01 Stereotaxis, Inc. Conflict Minerals Report For The Year Ended December 31, 2024 Introduction This Conflict Minerals Report for Stereotaxis, Inc. (“Stereotaxis”, “we,” “us,” and “our”) is for the period from January 1 to December 31, 2024 and is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule”). Terms used in this report are defined in the Rule and |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 16, 2025 STEREOTAXIS, INC. |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXI |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): May 12, 2025 STEREOTAXIS, INC. |
|
| May 12, 2025 |
Stereotaxis Reports 2025 First Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2025 First Quarter Financial Results St. Louis, MO, May 12, 2025 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. “We’ve started the year with solid execution on key commercial and innovation eff |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| March 14, 2025 |
Stereotaxis, Inc. Insider Trading Policy (filed herewith). Exhibit 19.1 STEREOTAXIS, INC. INSIDER TRADING POLICY (Adopted: September 2004, Amended May, 2005) Purpose The purpose of this policy is to ensure that Stereotaxis employees do not violate the insider trading laws by trading in securities of Stereotaxis or other companies while in possession of material nonpublic information. Violations of insider trading laws can result in severe civil and crimin |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS, IN |
|
| March 14, 2025 |
Exhibit 22.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: 1) Registration Statements (Form S-8 Nos. 333-197929, 333-213052, 333-219860 and 333-233847) of Stereotaxis, Inc. pertaining to the Stereotaxis, Inc. 2012 Stock Incentive Plan 2) Registration Statement (Form S-3 No. 333-233846) of Stereotaxis, |
|
| March 14, 2025 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes the common stock, $0.001 par value per share, of Stereotaxis, Inc. (the “Company,” “we,” “our,” “us,” and “our”), which are the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amen |
|
| March 3, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): March 3, 2025 STEREOTAXIS, INC. |
|
| March 3, 2025 |
Stereotaxis Reports 2024 Full Year Financial Results Exhibit 99.1 Stereotaxis Reports 2024 Full Year Financial Results St. Louis, MO, March 3, 2025 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2024. “We have started a milestone rich year in which we will demonstrat |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREO |
|
| November 12, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): November 12, 2024 STEREOTAXIS, INC. |
|
| November 12, 2024 |
Stereotaxis Reports 2024 Third Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2024 Third Quarter Financial Results St. Louis, Nov. 11, 2024 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2024. “The past quarter was marked by solid commercial execution, continued broad-base |
|
| September 9, 2024 |
September 9, 2024 Via EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Robert Augustin Re: Stereotaxis, Inc. Registration Statement on Form S-3 File No. 333-281766 Request for Acceleration of Effectiveness Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, Stereotaxis, Inc. (the “Company”) hereby requests tha |
|
| September 6, 2024 |
As filed with the Securities and Exchange Commission on September 6, 2024 As filed with the Securities and Exchange Commission on September 6, 2024 Registration No. |
|
| September 6, 2024 |
As filed with the Securities and Exchange Commission on September 6, 2024. As filed with the Securities and Exchange Commission on September 6, 2024. Registration No. 333-281766 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 PRE-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 STEREOTAXIS, INC. (Exact name of registrant as specified in its charter) Delaware 94-3120386 (State or other jurisdiction of inco |
|
| August 23, 2024 |
Stereotaxis, Inc. 2022 Employee Stock Purchase Plan, as amended and restated Exhibit 10.2 STEREOTAXIS, INC. 2022 EMPLOYEE STOCK PURCHASE PLAN As amended and restated effective February 15, 2024 1. Purpose. The purpose of this Stereotaxis, Inc. 2022 Employee Stock Purchase Plan (“Plan”) is to provide employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock through accumulated payroll deductions. It is the intention of the Company |
|
| August 23, 2024 |
As filed with the Securities and Exchange Commission on August 23, 2024. As filed with the Securities and Exchange Commission on August 23, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 STEREOTAXIS, INC. (Exact name of registrant as specified in its charter) Delaware 94-3120386 (State or other jurisdiction of incorporation or organization) (I.R.S. Employ |
|
| August 23, 2024 |
As filed with the Securities and Exchange Commission on August 23, 2024 As filed with the Securities and Exchange Commission on August 23, 2024 Registration No. |
|
| August 23, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Registration Statement on Form S-8 (Form Type) STEREOTAXIS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equ |
|
| August 23, 2024 |
Exhibit 24.1 POWER OF ATTORNEY Know All Persons By These Presents: That each person whose signature appears below, as a director or officer of Stereotaxis, Inc., a Delaware corporation (the “Company”), does hereby make, constitute and appoint David L. Fischel, Kimberly R. Peery and Laura S. Garth, and each or any one of them, his or her true and lawful attorney-in-fact and agent for the undersigne |
|
| August 23, 2024 |
Stereotaxis, Inc. 2022 Stock Incentive Plan, as amended and restated Exhibit 10.1 2022 STOCK INCENTIVE PLAN As amended and restated effective February 15, 2024 1. PURPOSE OF THE PLAN. The purpose of the Plan is to provide the Company with a means to assist in recruiting, retaining, and rewarding certain employees, directors, consultants, and other individuals providing services to the Company and to motivate such individuals to exert their best efforts on behalf of |
|
| August 23, 2024 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints David L. Fischel, Kimberly R. Peery and Laura Spencer Garth, and each of them (with full power of each to act alone), severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or he |
|
| August 23, 2024 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Security type Security class title Fee calculation rule Amount registered Proposed maximum offering price per share Maximum aggregate offering price Amount of registration fee Equity Common Stock, $0. |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS |
|
| August 14, 2024 |
Exhibit 2.1 EXECUTION VERSION CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) A TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”. Share Purchase Agreement among Stereotaxis, Inc., Access Point Technolo |
|
| August 14, 2024 |
Exhibit 2.2 AMENDMENT NO. 1 TO SHARE PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO SHARE PURCHASE AGREEMENT (this “Amendment”), dated as of July 31, 2024, is entered into by and among Stereotaxis, Inc., a Delaware corporation (“Purchaser”); Access Point Technologies EP, Inc., a Minnesota corporation (the “Company”); and APT Holding Company, Inc., a Minnesota corporation (“Seller”). Purchaser, Seller |
|
| August 12, 2024 |
Stereotaxis Reports 2024 Second Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2024 Second Quarter Financial Results ST. LOUIS, August 12, 2024 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2024. “We made significant progress over the last quarter on strategic innovation effor |
|
| August 12, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): August 12, 2024 STEREOTAXIS, INC. |
|
| August 2, 2024 |
Unregistered Sales of Equity Securities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 31, 2024 STEREOTAXIS, INC. |
|
| July 18, 2024 |
Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir Exhibit 99.1 Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir St. Louis, July 18, 2024 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum “Homi” Shamir to its Board of Directors. Mr. Shamir most recently served as Chairman and Chief Executive Officer of L |
|
| July 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 18, 2024 STEREOTAXIS, INC. |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Stereotaxis, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36159 94-3120386 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification No.) 710 N. Tucker Blvd, Suite 110; St. Louis, MO 63101 (Address of pr |
|
| May 30, 2024 |
Stereotaxis, Inc. Conflict Minerals Report for the reporting period January 1 to December 31, 2023 Exhibit 1.01 Stereotaxis, Inc. Conflict Minerals Report For The Year Ended December 31, 2023 Introduction This Conflict Minerals Report for Stereotaxis, Inc. (“Stereotaxis”, “we,” “us,” and “our”) is for the period from January 1 to December 31, 2023 and is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule”). Terms used in this report are defined in the Rule and |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 11, 2024 STEREOTAXIS, INC. |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXI |
|
| May 13, 2024 |
Stereotaxis Reports 2024 First Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2024 First Quarter Financial Results ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2024. “Stereotaxis is driving continued commercial, technological, and strategic progress,” |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): May 13, 2024 STEREOTAXIS, INC. |
|
| May 13, 2024 |
Stereotaxis Announces Definitive Agreement to Acquire Access Point Technologies Exhibit 99.2 Stereotaxis Announces Definitive Agreement to Acquire Access Point Technologies ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has entered into a definitive share purchase agreement under which Stereotaxis will acquire Access Point Technologi |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS, IN |
|
| March 8, 2024 |
Exhibit 22.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: 1) Registration Statement (Form S-8 No. 333-197930) of Stereotaxis, Inc. pertaining to the Stereotaxis, Inc. 2009 Employee Stock Purchase Plan 2) Registration Statements (Form S-8 Nos. 333-197929, 333-213052, 333-219860 and 333-233847) of Ster |
|
| March 8, 2024 |
Policy for Recovery of Erroneously Awarded Compensation (filed herewith). Exhibit 97.1 |
|
| March 4, 2024 |
Stereotaxis Reports 2023 Full Year Financial Results Exhibit 99.1 Stereotaxis Reports 2023 Full Year Financial Results ST. LOUIS, MO, Mar. 4, 2024 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2023. “We enter 2024 having made significant progress in realizing our st |
|
| March 4, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): March 4, 2024 STEREOTAXIS, INC. |
|
| February 14, 2024 |
STXS / Stereotaxis, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) STEREOTAXIS, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 85916J409 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 14, 2024 |
EX-99.1 2 tm245846d11ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 p |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREO |
|
| November 9, 2023 |
Stereotaxis Reports 2023 Third Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2023 Third Quarter Financial Results ST. LOUIS, Nov. 9, 2023 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2023. “Stereotaxis continues to deliver commercial results and advance a robust innovat |
|
| November 9, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): November 9, 2023 STEREOTAXIS, INC. |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS |
|
| August 10, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): August 10, 2023 STEREOTAXIS, INC. |
|
| August 10, 2023 |
Stereotaxis Reports 2023 Second Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2023 Second Quarter Financial Results ST. LOUIS, August 10, 2023 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2023. “Stereotaxis delivered 28% revenue growth in the quarter, driven by a healthy sys |
|
| June 15, 2023 |
Stereotaxis to Initiate First-in-Human Trial to Support CE Mark Application of MAGiC Catheter Exhibit 99.1 Stereotaxis to Initiate First-in-Human Trial to Support CE Mark Application of MAGiC Catheter St. Louis, June 15, 2023 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it intends to initiate a first-in-human trial to support the CE Mark submission for its MAGiC™ catheter |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): June 15, 2023 STEREOTAXIS, INC. |
|
| June 2, 2023 |
June 2, 2023 Via EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Nicholas O’Leary Re: Stereotaxis, Inc. Registration Statement on Form S-3 Filed May 19, 2023 (Commission File No. 333-272102) Dear Sir or Madam: In accordance with Rule 461 under the Securities Act of 1933, as amended, Stereotaxis, Inc. (the “Company”) hereby requests that the Registratio |
|
| June 2, 2023 |
June 2, 2023 Via EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Nicholas O’Leary Re: Stereotaxis, Inc. Registration Statement on Form S-3 Filed May 19, 2023 (Commission File No. 333-272101) Dear Sir or Madam: In accordance with Rule 461 under the Securities Act of 1933, as amended, Stereotaxis, Inc. (the “Company”) hereby requests that the Registratio |
|
| June 1, 2023 |
As filed with the Securities and Exchange Commission on June 1, 2023. As filed with the Securities and Exchange Commission on June 1, 2023. Registration No. 333-272101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 PRE-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 STEREOTAXIS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or org |
|
| May 26, 2023 |
Stereotaxis, Inc. Conflict Minerals Report for the reporting period January 1 to December 31, 2022 Exhibit 1.01 Stereotaxis, Inc. Conflict Minerals Report For The Year Ended December 31, 2022 Introduction This Conflict Minerals Report for Stereotaxis, Inc. (“Stereotaxis”, “we,” “us,” and “our”) is for the period from January 1 to December 31, 2022 and is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule”). Terms used in this report are defined in the Rule and |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Stereotaxis, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36159 94-3120386 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification No.) 710 N. Tucker Blvd, Suite 110; St. Louis, MO 63101 (Address of pr |
|
| May 19, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered (1) Proposed maximum offering price per unit (2) Proposed maximum aggregate offering price (3) Amount of registration fee(4) Debt Securities (5) Common Stock (5) Preferred Stock(5) $ 100,000,000 — $ 100,000,000 $ 11,020 Warrants (5)(6) Rights Units (7) (1) There are being registered hereunder such indeterminate number of shares of common stock and preferred stock of Stereotaxis, Inc. |
|
| May 19, 2023 |
Consent of Bryan Cave Leighton Paisner LLP (included in Exhibit 5.3). Exhibit 5.3 May 19, 2023 Stereotaxis, Inc. 710 North Tucker Boulevard, Suite 110 St. Louis, Missouri 63101 Re: Stereotaxis, Inc. Registration Statement on Form S-3 Ladies and Gentlemen: We refer to the Registration Statement on Form S-1 (File No. 333-214255) (the “Initial Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 19, 2023 STEREOTAXIS, INC. |
|
| May 19, 2023 |
As filed with the Securities and Exchange Commission on May 19, 2023. As filed with the Securities and Exchange Commission on May 19, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 STEREOTAXIS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 94-3120386 (I.R.S. Employer |
|
| May 19, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered (1) Proposed maximum offering price per unit Proposed maximum aggregate offering price Amount of registration fee Common Stock underlying Series A Convertible Preferred Stock (2) 44,921,439 — (3) — — Common Stock issued upon exercise of certain warrants (4) 36,300,000 — (5) — — Common Stock underlying Series A Convertible Preferred Stock (6) 10,000,000 1. |
|
| May 19, 2023 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints David L. Fischel, Kimberly R. Peery and Laura Spencer Garth, and each of them (with full power of each to act alone), severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or he |
|
| May 19, 2023 |
As filed with the Securities and Exchange Commission on May 19, 2023 As filed with the Securities and Exchange Commission on May 19, 2023 Registration No. |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXI |
|
| May 9, 2023 |
Stereotaxis Reports 2023 First Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2023 First Quarter Financial Results ST. LOUIS, May 9, 2023 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2023. “Stereotaxis continues to make significant progress on its robust innovation strategy. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): May 9, 2023 STEREOTAXIS, INC. |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 5, 2023 |
definitive Proxy Statement on Form 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| March 9, 2023 |
Exhibit 10.1c INCENTIVE STOCK OPTION TERMS OF AWARD UNDER STEREOTAXIS, INC. 2022 STOCK INCENTIVE PLAN Stereotaxis, Inc. (the “Company”) has made an Award to the Participant of Incentive Stock Options (the “Option”) under the Stereotaxis, Inc. 2022 Stock Incentive Plan (the “Plan”). The date of grant, the number of shares of Stock (“Shares”) covered by the Option, and the exercise price of the Opti |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS, IN |
|
| March 9, 2023 |
Exhibit 10.1d NON-QUALIFIED STOCK OPTION TERMS OF AWARD UNDER STEREOTAXIS, INC. 2022 STOCK INCENTIVE PLAN Stereotaxis, Inc. (the “Company”) has made an Award to the Participant of Non-Qualified Stock Options (the “Option”) under the Stereotaxis, Inc. 2022 Stock Incentive Plan (the “Plan”). The date of grant, the number of shares of Stock (“Shares”) covered by the Option, and the exercise price of |
|
| March 9, 2023 |
Exhibit 22.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: 1) Registration Statement (Form S-8 No. 333-197930) of Stereotaxis, Inc. pertaining to the Stereotaxis, Inc. 2009 Employee Stock Purchase Plan 2) Registration Statements (Form S-8 Nos. 333-197929, 333-213052, 333-219860 and 333-233847) of Ster |
|
| March 9, 2023 |
Exhibit 10.1b RESTRICTED SHARE UNIT TERMS OF AWARD UNDER STEREOTAXIS, INC. 2022 STOCK INCENTIVE PLAN DIRECTOR AWARD On (“Grant Date”), the Company granted to Director an Award of restricted share units (“RSUs”) under the Stereotaxis, Inc. 2022 Stock Incentive Plan (the “Plan”). The date of grant and the number of RSUs covered by this Award are set forth in the Award letter you received from the Co |
|
| March 3, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): March 3, 2023 STEREOTAXIS, INC. |
|
| March 3, 2023 |
Stereotaxis Reports 2022 Full Year Financial Results Exhibit 99.1 Stereotaxis Reports 2022 Full Year Financial Results ST. LOUIS, MO, Mar. 3, 2023 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2022. “This year is poised to be an important and exciting year for Stere |
|
| February 14, 2023 |
EX-99.1 2 tm236041d22ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 p |
|
| February 14, 2023 |
STXS / Stereotaxis Inc / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm236041d22sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) STEREOTAXIS, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 85916J409 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREO |
|
| November 10, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): November 10, 2022 STEREOTAXIS, INC. |
|
| November 10, 2022 |
Stereotaxis Reports 2022 Third Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2022 Third Quarter Financial Results ST. LOUIS, MO, Nov. 10, 2022 (GLOBE NEWSWIRE) ? Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2022. ?Stereotaxis continues to demonstrate robust commercial and technological pr |
|
| August 11, 2022 |
As filed with the Securities and Exchange Commission on August 11, 2022 S-8 1 forms-8.htm As filed with the Securities and Exchange Commission on August 11, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 STEREOTAXIS, INC. (Exact name of registrant as specified in its charter) Delaware 94-3120386 (State or other jurisdiction of incorporation or organizat |
|
| August 11, 2022 |
Exhibit 24.1 POWER OF ATTORNEY Know All Persons By These Presents: That each person whose signature appears below, as a director or officer of Stereotaxis, Inc., a Delaware corporation (the ?Company?), does hereby make, constitute and appoint David L. Fischel, Kimberly R. Peery and Laura S. Garth, and each or any one of them, his or her true and lawful attorney-in-fact and agent for the undersigne |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS |
|
| August 11, 2022 |
Exhibit 10.1 2022 STOCK INCENTIVE PLAN 1. PURPOSE OF THE PLAN. The purpose of the Plan is to provide the Company with a means to assist in recruiting, retaining, and rewarding certain employees, directors, consultants, and other individuals providing services to the Company and to motivate such individuals to exert their best efforts on behalf of the Company by providing incentives through the gra |
|
| August 11, 2022 |
EX-FILING FEES 5 ex107-1.htm Exhibit 107.1 Calculation of Filing Fee Tables Registration Statement on Form S-8 (Form Type) STEREOTAXIS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate A |
|
| August 11, 2022 |
Exhibit 10.2 STEREOTAXIS, INC. 2022 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of this Stereotaxis, Inc. 2022 Employee Stock Purchase Plan (?Plan?) is to provide employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock through accumulated payroll deductions. It is the intention of the Company to have the Plan qualify as an ?employee stock purc |
|
| August 9, 2022 |
Stereotaxis Reports 2022 Second Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2022 Second Quarter Financial Results ST. LOUIS, MO, Aug. 9, 2022 (GLOBE NEWSWIRE) ? Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2022. ?Despite macro pressures and the poor optics of our financial results, Stereotax |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): August 9, 2022 STEREOTAXIS, INC. |
|
| May 27, 2022 |
Stereotaxis, Inc. Conflict Minerals Report for the reporting period January 1 to December 31, 2021 Exhibit 1.01 Stereotaxis, Inc. Conflict Minerals Report For The Year Ended December 31, 2021 Introduction This Conflict Minerals Report for Stereotaxis, Inc. (“Stereotaxis”, “we,” “us,” and “our”) is for the period from January 1 to December 31, 2021 and is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule”). Terms used in this report are defined in the Rule and |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Stereotaxis, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36159 94-3120386 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification No.) 710 N. Tucker Blvd, Suite 110; St. Louis, MO 63101 (Address of pr |
|
| May 19, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 19, 2022 STEREOTAXIS, INC. |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXI |
|
| May 10, 2022 |
Stereotaxis Reports 2022 First Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2022 First Quarter Financial Results ST. LOUIS, May 10, 2022 (GLOBE NEWSWIRE) ? Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2022. ?Stereotaxis demonstrated continued progress on capital adoption despite a challengin |
|
| May 10, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): May 10, 2022 STEREOTAXIS, INC. |
|
| April 8, 2022 |
DEFA14A 1 formdefa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement |
|
| April 8, 2022 |
DEF 14A 1 formdef14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS, IN |
|
| March 10, 2022 |
Exhibit 10.12i SECOND AMENDMENT TO LEASE AGREEMENT THIS SECOND AMENDMENT TO LEASE AGREEMENT (the ?Second Amendment?) is made as of the day of October, 2021 (?Effective Date?), by and between Globe Building Company, a Missouri general partnership (?Landlord?), and Stereotaxis, Inc., a Delaware corporation (?Tenant?). WITNESSETH: WHEREAS, Landlord and Tenant entered into that certain Lease Agreement |
|
| March 3, 2022 |
Stereotaxis Reports 2021 Full Year Financial Results Exhibit 99.1 Stereotaxis Reports 2021 Full Year Financial Results ST. LOUIS, Mar. 3, 2022 (GLOBE NEWSWIRE) ? Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2021. ?In 2021 we delivered significant revenue growth, drove a resurgence in |
|
| March 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): March 3, 2022 STEREOTAXIS, INC. |
|
| February 14, 2022 |
STXS / Stereotaxis Inc / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3) STEREOTAXIS, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 85916J409 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 14, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.001 par value per share, of Stereotaxis, Inc., whi |
|
| February 3, 2022 |
STXS / Stereotaxis Inc / Arbiter Partners Capital Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3) Stereotaxis, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 85916J409 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| November 12, 2021 |
Stereotaxis Reports 2021 Third Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2021 Third Quarter Financial Results ST. LOUIS, Nov. 11, 2021 (GLOBE NEWSWIRE) ? Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2021. ?We are proud of the progress made on multiple fronts in the third quarter,? said Da |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): November 11, 2021 STEREOTAXIS, INC. |
|
| November 12, 2021 |
Exhibit 10.1 NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM The Stereotaxis, Inc. Non-Employee Director Compensation program effective July 1, 2021: Annual Awards of Restricted Share Units (?RSUs?) Annual award to each director RSUs equal to $200,000 All equity awards to directors will be issued under the Stereotaxis, Inc. 2012 Stock Incentive Plan or a successor Plan. Annual equity awards will be mad |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREO |
|
| August 27, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): August 26, 2021 STEREOTAXIS, INC. |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS |
|
| August 12, 2021 |
As filed with the Securities and Exchange Commission on August 12, 2021 As filed with the Securities and Exchange Commission on August 12, 2021 Registration No. |
|
| August 12, 2021 |
Exhibit 24.1 POWER OF ATTORNEY Know All Persons By These Presents: That each person whose signature appears below, as a director or officer of Stereotaxis, Inc., a Delaware corporation (the ?Company?), does hereby make, constitute and appoint David L. Fischel and Kimberly R. Peery, and each or any one of them, his or her true and lawful attorney-in-fact and agent for the undersigned, with full pow |
|
| August 12, 2021 |
Exhibit 10.1 STEREOTAXIS, INC. 2012 STOCK INCENTIVE PLAN As amended and restated effective February 11, 2021 1. Purpose of the Plan. The purpose of the Plan is to provide the Company with a means to assist in recruiting, retaining, and rewarding certain employees, directors, consultants, and other individuals providing services to the Company and to motivate such individuals to exert their best ef |
|
| August 10, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): August 10, 2021 STEREOTAXIS, INC. |
|
| August 10, 2021 |
Stereotaxis Reports 2021 Second Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2021 Second Quarter Financial Results ST. LOUIS, MO, Aug. 10, 2021 (GLOBE NEWSWIRE) ? Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2021. ?Renewed global adoption of robotic systems continues to drive robust double digit |
|
| July 26, 2021 |
Stereotaxis Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D. Exhibit 99.1 Stereotaxis Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D. St. Louis, July 26, 2021 (GLOBE NEWSWIRE) ? Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Myriam J. Curet, M.D., to its Board of Directors. Dr. Curet currently serves as Executive Vice Preside |
|
| July 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): July 26, 2021 STEREOTAXIS, INC. |
|
| June 16, 2021 |
STXS / Stereotaxis Inc / KIANI JOE E - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* STEREOTAXIS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 85916J409 (CUSIP Number) June 9, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| May 20, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 20, 2021 STEREOTAXIS, INC. |
|
| May 17, 2021 |
Stereotaxis, Inc. Conflict Minerals Report for the reporting period January 1 to December 31, 2020 EX-1.01 2 ex1-01.htm Exhibit 1.01 Stereotaxis, Inc. Conflict Minerals Report For The Year Ended December 31, 2020 Introduction This Conflict Minerals Report for Stereotaxis, Inc. (“Stereotaxis”, “we,” “us,” and “our”) is for the period from January 1 to December 31, 2020 and is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule”). Terms used in this report are def |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Stereotaxis, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36159 94-3120386 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification No.) 4320 Forest Park Avenue; Suite 100; St. Louis, MO 63108 (Address |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXI |
|
| May 13, 2021 |
Exhibit 10.1b FIRST AMENDMENT TO LEASE AGREEMENT THIS FIRST AMENDMENT TO LEASE AGREEMENT (the ?First Amendment?) is made as of the 30th day of March 2021, by and between Globe Building Company, a Missouri general partnership (?Landlord?), and Stereotaxis, Inc., a Delaware corporation (?Tenant?). WITNESSETH: WHEREAS, Landlord and Tenant entered into that certain Lease Agreement dated March 1, 2021 |
|
| May 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): May 10, 2021 STEREOTAXIS, INC. |
|
| May 10, 2021 |
Stereotaxis Reports 2021 First Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2021 First Quarter Financial Results ST. LOUIS, MO, May 10, 2021 (GLOBE NEWSWIRE) ? Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2021. ?The highlight of the first quarter is Stereotaxis? return to robust double digit rev |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 9, 2021 |
DEF 14A 1 def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement |
|
| April 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, fo |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS, IN |
|
| March 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): March 4, 2021 STEREOTAXIS, INC. |
|
| March 4, 2021 |
Exhibit 10.1 LEASE (Table of Contents) 1. Basic Lease Data; Premises; Measurement; Memorandum. 9 2. Term, Commencement Date; Tenant?s Delay. 9 3. Rental 10 4. Building Amenities 10 5. Operating Cost Reimbursement; Tax Reimbursement; Insurance Reimbursement. 10 6. Use 14 7. Common Areas 14 8. Rules and Regulations 14 9. Landlord?s Delivery Condition Work; Tenant Improvements Allowances, AS IS. 15 1 |
|
| February 25, 2021 |
Stereotaxis Reports 2020 Full Year Financial Results Exhibit 99.1 Stereotaxis Reports 2020 Full Year Financial Results St. Louis, Feb. 25, 2021 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2020. “2020 was a year of significant progress despite a challenging macro envir |
|
| February 25, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): February 25, 2021 STEREOTAXIS, INC. |
|
| February 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): February 23, 2021 STEREOTAXIS, INC. |
|
| February 24, 2021 |
Stereotaxis Announces Long-Term CEO Performance Stock Award Exhibit 99.1 Stereotaxis Announces Long-Term CEO Performance Stock Award St. Louis, Feb. 24, 2021 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a 10-year CEO performance stock award for David Fischel with vesting entirely contingent upon the company achieving billion-dollar market capitali |
|
| February 24, 2021 |
Exhibit 10.1 PERFORMANCE SHARE UNIT AWARD AGREEMENT Stereotaxis, Inc. (the ?Company?) has granted David Leo Fischel (the ?Participant?) an award for a target number of 13,000,000 Performance Share Units (the ?Target Award?) as of 02/23/2021 (the ?Grant Date?). Each Performance Share Unit (?PSU?) represents the right to receive one share of common stock of the Company, par value $0.001 per share (t |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) Stereotaxis, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 85916J409 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) STEREOTAXIS, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 85916J409 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 16, 2021 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value per share, of Stereotaxis, Inc., whi |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) STEREOTAXIS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 85916J409 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| December 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): December 17, 2020 STEREOTAXIS, INC. |
|
| December 18, 2020 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of this 17th day of December, 2020, by and between Stereotaxis, Inc., a Delaware corporation (the “Company”), and David L. Fischel (“Employee”). RECITAL WHEREAS, the parties desire to enter into this Agreement setting forth the terms and conditions for the employment relationship between E |
|
| November 9, 2020 |
Stereotaxis Reports 2020 Third Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2020 Third Quarter Financial Results ST. LOUIS, MO, Nov. 9, 2020 – (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2020. “Stereotaxis is pleased to report revenue growth with the successful installati |
|
| November 9, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): November 9, 2020 STEREOTAXIS, INC. |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREO |
|
| August 6, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): August 6, 2020 STEREOTAXIS, INC. |
|
| August 6, 2020 |
Stereotaxis Reports 2020 Second Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2020 Second Quarter Financial Results St. Louis, MO, Aug. 6, 2020 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2020. “Stereotaxis responded to the challenges of COVID-19 with resilience, prudence and c |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS |
|
| May 26, 2020 |
Stereotaxis Announces $15 Million Common Stock Financing Exhibit 99.1 Stereotaxis Announces $15 Million Common Stock Financing ST. LOUIS, May 26, 2020 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement with certain funds managed by Consonance Capital Management, a prominent healthcare-focused i |
|
| May 26, 2020 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of May 25, 2020, by and between Stereotaxis, Inc., a Delaware corporation (the “Company”), and the investors executing the signature page attached hereto (each an “Investor” and together, collectively, the “Investors”). WHEREAS, the Company has filed with the Securities and Exchange Commission (th |
|
| May 26, 2020 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): May 25, 2020 STEREOTAXIS, INC. |
|
| May 26, 2020 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-237194 PROSPECTUS SUPPLEMENT (To the prospectus dated April 13, 2020) 3,658,537 Shares COMMON STOCK We are selling 3,658,537 shares of our common stock to certain investors pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is quoted on the NYSE American under the symbol “STXS.” The last reported sale price |
|
| May 22, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 21, 2020 STEREOTAXIS, INC. |
|
| May 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Stereotaxis, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36159 94-3120386 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification No.) 4320 Forest Park Avenue; Suite 100; St. Louis, MO 63108 (Address |
|
| May 14, 2020 |
Stereotaxis, Inc. Conflict Minerals Report for the reporting period January 1 to December 31, 2019 Exhibit 1.01 Stereotaxis, Inc. Conflict Minerals Report For The Year Ended December 31, 2019 Introduction This Conflict Minerals Report for Stereotaxis, Inc. (“Stereotaxis”, “we,” “us,” and “our”) is for the period from January 1 to December 31, 2019 and is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule”). Terms used in this report are defined in the Rule and |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREO |
|
| May 11, 2020 |
Exhibit 10.1 |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): April 14, 2020 STEREOTAXIS, INC. |
|
| May 7, 2020 |
SEPARATION AGREEMENT AND RELEASE OF ALL CLAIMS Exhibit 99.1 SEPARATION AGREEMENT AND RELEASE OF ALL CLAIMS This Separation Agreement and Release of All Claims (“Agreement”) is made between Stereotaxis, Inc., including its divisions, subsidiaries, parent and affiliated corporations, successors and assigns (individually and collectively, “Stereotaxis”) and Kevin M. Barry (“Employee”) (hereinafter collectively referred to as “the Parties”). WHERE |
|
| May 5, 2020 |
Stereotaxis Reports 2020 First Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2020 First Quarter Financial Results ST. LOUIS, MO, May 5, 2020 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2020. “Despite the challenges and disruptions inflicted by COVID-19, Stereotaxis continues t |
|
| May 5, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): May 5, 2020 STEREOTAXIS, INC. |
|
| April 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): April 14, 2020 STEREOTAXIS, INC. |
|
| April 9, 2020 |
STXS / Stereotaxis, Inc. DEFA14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, fo |
|
| April 9, 2020 |
Exhibit 4.7 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes the common stock, $0.001 par value per share, of Stereotaxis, Inc. (the “Company,” “we,” “our,” “us,” and “our”), which are the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amen |
|
| April 9, 2020 |
STXS / Stereotaxis, Inc. 10-K/A - Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 (MARK ONE) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001 |
|
| April 9, 2020 |
STXS / Stereotaxis, Inc. DEF 14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, fo |
|
| April 9, 2020 |
April 9, 2020 Via EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Paul Fischer Re: Stereotaxis, Inc. Registration Statement on Form S-3 Filed March 16, 2020 (Commission File No. 333-237194) Dear Sir or Madam: In accordance with Rule 461 under the Securities Act of 1933, as amended, Stereotaxis, Inc. (the “Company”) hereby requests that the Registration |
|
| March 16, 2020 |
CORRESP 1 filename1.htm March 16, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Stereotaxis, Inc. Registration Statement on Form S-3 Ladies and Gentlemen: We are writing this transmittal letter on behalf of Stereotaxis, Inc. (the “Company”) in connection with its filing today, via EDGAR, of its Form S-3 Registra |
|
| March 16, 2020 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints David L. Fischel, Kimberly R. Peery and Kevin M. Barry, and each of them (with full power of each to act alone), severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and |
|
| March 16, 2020 |
STXS / Stereotaxis, Inc. S-3 - - As filed with the Securities and Exchange Commission on March 16, 2020 Registration No. |
|
| March 16, 2020 |
STXS / Stereotaxis, Inc. 10-K - Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS |
|
| March 16, 2020 |
Exhibit 4.7 Anti-Takeover Provisions of Delaware Law and Charter Provisions Interested Stockholder Transactions. We are subject to Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any “business combination” with any “interested stockholder” for a period of three years after the date that such stockholder became an interested stockholder, |
|
| March 10, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): March 10, 2020 STEREOTAXIS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36159 94-3120386 (C |
|
| March 10, 2020 |
Stereotaxis Reports 2019 Full Year Financial Results Exhibit 99.1 Stereotaxis Reports 2019 Full Year Financial Results ST. LOUIS, MO, March 10, 2020 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2019. “The past year was transformative for Stereotaxis with significant pr |
|
| February 14, 2020 |
STXS / Stereotaxis, Inc. / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) STEREOTAXIS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 85916J409 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2020 |
STXS / Stereotaxis, Inc. / Redmile Group, LLC - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) STEREOTAXIS, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 85916J409 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| November 14, 2019 |
STXS / Stereotaxis, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36159 STEREOTAXIS, IN |
|
| November 14, 2019 |
Stereotaxis Reports 2019 Third Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2019 Third Quarter Financial Results ST. LOUIS, MO, Nov. 14, 2019 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2019. “The third quarter was highlighted by successful reengagement with the capital m |
|
| November 14, 2019 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2019 STEREOTAXIS, INC. |
|
| October 4, 2019 |
Common Stock, $0.001 par value 12,195,121 Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-233846 PROSPECTUS Common Stock, $0.001 par value 12,195,121 Shares This prospectus relates to the resale, from time to time, of 12,195,121 shares of our common stock by the selling stockholders named herein. On August 7, 2019, we entered into a securities purchase agreement with the investors listed on the Schedule of Buyers thereto (together t |
|
| October 2, 2019 |
STXS / Stereotaxis, Inc. CORRESP - - 4320 Forest Park Avenue, Suite 100 St. Louis, Missouri 63108 October 2, 2019 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Stereotaxis, Inc. Registration Statement on Form S-3 (Commission File No. 333-233846) Dear Sir or Madam: In accordance with Rule 461 under the Securities Act of 1933, as amen |
|
| September 19, 2019 |
Exhibit 24.1 POWER OF ATTORNEY Know All Persons By These Presents: That each person whose signature appears below, as a director or officer of Stereotaxis, Inc., a Delaware corporation (the “Company”), does hereby make, constitute and appoint David L. Fischel, Martin C. Stammer and Kevin M. Barry, and each or any one of them, his or her true and lawful attorney-in-fact and agent for the undersigne |
|
| September 19, 2019 |
STXS / Stereotaxis, Inc. S-8 - - As filed with the Securities and Exchange Commission on September 19, 2019 Registration No. |
|
| September 19, 2019 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints David L. Fischel, Martin C. Stammer and Kevin M. Barry, and each of them (with full power of each to act alone), severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and |
|
| September 19, 2019 |
STXS / Stereotaxis, Inc. S-3 - - As filed with the Securities and Exchange Commission on September 19, 2019. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 STEREOTAXIS, INC. Delaware (State or other jurisdiction of incorporation or organization) 3845 (Primary Standard Industrial Classification Code number) 94-3120386 (I.R |
|
| September 16, 2019 |
Stereotaxis Announces CFO Transition Exhibit 99.1 Stereotaxis Announces CFO Transition ST. LOUIS, MO, Sept. 16, 2019 – Stereotaxis (NYSE American: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that Kimberly Peery has been appointed Stereotaxis Chief Financial Officer, effective October 1, 2019. Martin Stammer, who has served as Chief Financial Officer since 2013, |
|
| September 16, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 12, 2019 STEREOTAXIS, INC. |
|
| September 4, 2019 |
STXS / Stereotaxis, Inc. 8-A12B - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 STEREOTAXIS, INC. (Exact name of registrant as specified in its charter) Delaware 94-3120386 (State of incorporation or organization) (IRS Employer Identification No.) 4320 Forest Park Avenue Sui |
|
| August 22, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2019 STEREOTAXIS, INC. |
|
| August 22, 2019 |
STEREOTAXIS, INC. BALANCE SHEET UNAUDITED ACTUAL AND AS ADJUSTED JUNE 30, 2019 Exhibit 99.1 STEREOTAXIS, INC. BALANCE SHEET UNAUDITED ACTUAL AND AS ADJUSTED JUNE 30, 2019 June 30, 2019 as reported Adjustments as a result of August financing June 30, 2019 including August financing (Unaudited) (Unaudited) (Unaudited) Assets Current assets: Cash and cash equivalents $ 8,471,914 $ 23,130,000 (1) $ 31,601,914 Accounts receivable, net of allowance of $502,251 4,997,148 4,997,148 |
|
| August 16, 2019 |
STXS / Stereotaxis, Inc. / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 STEREOTAXIS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 85916J409 (CUSIP Number) August 7, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| August 12, 2019 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value per share, of Stereotaxis, Inc., whi |
|
| August 12, 2019 |
STXS / Stereotaxis, Inc. / Redmile Group, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) STEREOTAXIS, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 85916J409 (CUSIP Number) August 7, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| August 9, 2019 |
STXS / Stereotaxis, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36159 STEREOTAXIS, INC. (E |
|
| August 8, 2019 |
Stereotaxis Reports 2019 Second Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2019 Second Quarter Financial Results ST. LOUIS, MO, August 8, 2019 – Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2019. In a separate press release issued concurrently with this release, Stereotaxis announced a $25 mil |
|
| August 8, 2019 |
Results of Operations and Financial Condition, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2019 STEREOTAXIS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36159 94-3120386 (C |
|
| August 8, 2019 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of August 7, 2019, by and among Stereotaxis, Inc., a Delaware corporation, with headquarters located at 4320 Forest Park Avenue, Suite 100, St. Louis, MO 63108 (the “Company”), and the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers” |
|
| August 8, 2019 |
Exhibit 3.1 STEREOTAXIS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW STEREOTAXIS, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify that, in accord |
|
| August 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2019 STEREOTAXIS, INC. |
|
| August 8, 2019 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 7, 2019, by and among Stereotaxis, Inc., a Delaware corporation, with principal office located at 4320 Forest Park Avenue, Suite 100, St. Louis, MO 63108 (the “Company”), and the undersigned buyers (each, a “Buyer” and, collectively, the “Buyers”). WHEREAS: A. In connection with the Secu |
|
| August 8, 2019 |
Stereotaxis Announces $25 Million Private Placement Exhibit 99.1 Stereotaxis Announces $25 Million Private Placement ST. LOUIS, MO, August 8, 2019 – Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement with select institutional investors for a $25 million private placement. In this private placement, Stereota |
|
| July 1, 2019 |
Exhibit 10.1 SECOND Amendment TO and Reinstatement of THIRD AMENDED AND RESTATED LOAN AND SECURITY agreement This Second Amendment to and Reinstatement of Third Amended and Restated Loan and Security Agreement (this “Amendment”) is entered into this 27th day of June, 2019, by and among (i) SILICON VALLEY BANK, a California corporation with its principal place of business at 3003 Tasman Drive, Sant |
|
| July 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 27, 2019 STEREOTAXIS, INC. |
|
| May 21, 2019 |
Submission of Matters to a Vote of Security Holders 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 21, 2019 STEREOTAXIS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36159 94-3120386 (Com |
|
| May 15, 2019 |
Stereotaxis, Inc. Conflict Minerals Report for the reporting period January 1 to December 31, 2018 EX-1.01 2 ex1-01.htm Exhibit 1.01 Stereotaxis, Inc. Conflict Minerals Report For The Year Ended December 31, 2018 Introduction This Conflict Minerals Report for Stereotaxis, Inc. (“Stereotaxis”, “we,” “us,” and “our”) is for the period from January 1 to December 31, 2018 and is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule”). Terms used in this report are def |
|
| May 15, 2019 |
SD 1 formsd.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Stereotaxis, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36159 94-3120386 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification No.) 4320 Forest Park Avenue; Suite 100; St. Louis, MO |
|
| May 9, 2019 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2019 STEREOTAXIS, INC. |
|
| May 9, 2019 |
Stereotaxis Reports 2019 First Quarter Financial & Operational Results Exhibit 99.1 Stereotaxis Reports 2019 First Quarter Financial & Operational Results ST. LOUIS, MO, May 9, 2019 – Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2019. In separate press releases issued concurrently with this release, Stereotaxis showcased |
|
| May 9, 2019 |
STXS / Stereotaxis, Inc. 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36159 STEREOTAXIS, INC. ( |
|
| April 10, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, fo |
|
| April 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, fo |
|
| March 27, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, fo |
|
| March 15, 2019 |
STXS / Stereotaxis, Inc. (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS |
|
| March 12, 2019 |
Stereotaxis Reports 2018 Full Year Financial Results EX-99.1 2 ex99-1.htm Exhibit 99.1 Stereotaxis Reports 2018 Full Year Financial Results ● Record high annual recurring revenue of $27.8 million; 3% annual growth ● Positive annual net income for the first time in Company history despite significantly increased R&D investments ● Innovation initiatives to be showcased in May at Heart Rhythm Society meeting ● Strong financial position to reach profita |
|
| March 12, 2019 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2019 STEREOTAXIS, INC. |
|
| February 14, 2019 |
STXS / Stereotaxis, Inc. / Arbiter Partners Capital Management LLC - SC 13G/A Passive Investment Arbiter Partners Capital Management LLC: Schedule 13G/A - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Stereotaxis, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 85916J409 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this St |
|
| January 11, 2019 |
Exhibit 10.1 FIFTH AMENDMENT TO OFFICE LEASE THIS FIFTH AMENDMENT TO OFFICE LEASE (this “Amendment”) is entered into as of this 10th day of January, 2019, by and between VTR LS 4320 FOREST PARK, LLC, a Delaware limited liability company (“Landlord”), as successor-in-interest to Cortex West Development I, LLC (“Original Landlord”), and STEREOTAXIS, INC., a Delaware corporation (“Tenant”). RECITALS |
|
| January 11, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2019 STEREOTAXIS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36159 94-3120386 |
|
| November 13, 2018 |
Stereotaxis Reports 2018 Third Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2018 Third Quarter Financial Results ● Continued progress on strategic innovation initiatives; expect to showcase in 1H 2019 ● 4% recurring revenue growth; reaffirming 2018 record recurring revenue expectations ● Conference call today at 10:00 a.m. Eastern Time ST. LOUIS, MO, Nov. 12, 2018 – Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic t |
|
| November 13, 2018 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2018 STEREOTAXIS, INC. |
|
| November 13, 2018 |
STXS / Stereotaxis, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-361 |
|
| November 13, 2018 |
Terms and Conditions of Employment for Kevin Barry, Chief Legal Officer, filed herewith. Exhibit 10.2 Terms and Conditions of Employment 1) Scope. Kevin Barry (“Employee”) accepts and agrees to the terms of the Stereotaxis offer letter dated 9/26/2018 (“Offer Letter”). Both parties agree that Employee’s employment by Stereotaxis, Inc. (the “Company” or “Stereotaxis”) shall be subject to these terms and conditions set out herein. (The Offer Letter and these Terms and Conditions togethe |
|
| November 13, 2018 |
Employment Offer Letter for Kevin Barry, Chief Legal Officer, filed herewith. EX-10.1 2 ex10-1.htm Exhibit 10.1 September 26, 2018 Kevin Barry 2200 S 2200 E Salt Lake City, UT 54109 Dear Kevin: I am pleased to extend you an offer to join Stereotaxis as Chief Legal Officer & Secretary reporting to me in my capacity as CEO. Your position will be based out of our St. Louis, MO, facility. This letter outlines the terms of your employment offer with an effective start date prior |
|
| October 30, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2018 STEREOTAXIS, INC. |
|
| August 8, 2018 |
STXS / Stereotaxis, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36159 ST |
|
| August 7, 2018 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2018 STEREOTAXIS, INC. |
|
| August 7, 2018 |
Stereotaxis Reports 2018 Second Quarter Financial Results Exhibit 99.1 Stereotaxis Reports 2018 Second Quarter Financial Results ● Progress on strategic internal innovation and external collaborations ● Continued growth in recurring revenue ● Positive cash flow from operations ● Reaffirming 2018 expectations ● Conference call today at 10:00 a.m. Eastern Time ST. LOUIS, MO, Aug. 7, 2018 – Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative ro |
|
| June 25, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 19, 2018 STEREOTAXIS, INC. |
